

Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting

Oct 24, 2011 9:20am

Pharma

SAN DIEGO, Oct. 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the [extracellular matrix](http://www.halozyme.com/aboutus.php) (<http://www.halozyme.com/aboutus.php>), for the diabetes, cancer, dermatology and drug delivery markets, today announced its upcoming poster presentation for PEGPH20 at the 2011 EORTC-NCI-ASCO Annual Meeting, taking place October 27-29 in Brussels, Belgium. Halozyme's PEGPH20 is a PEGylated form of rHuPH20 that is being evaluated in an ongoing Phase 2 clinical trial in patients with stage IV previously untreated pancreatic cancer. The poster and abstract will also be published in the "European Journal of Cancer" proceeding book of the conference. Details of the poster session and discussion are as follows:

Thursday, October 27, 2011

12:00 – 8:30 p.m. CET: **Targeting hyaluronan in tumor stroma. Interim translational and biomarker evaluations of pegylated hyaluronidase (PEGPH20) in patients with advanced solid tumors** (Discussion from 6:00 – 8:30 p.m. CET)

(Logo: <http://photos.prnewswire.com/prnh/20100302/LA63139LOGO> (<http://photos.prnewswire.com/prnh/20100302/LA63139LOGO>))

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze(TM) technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target multiple areas of significant unmet medical need. For more information visit www.halozyme.com (<http://www.halozyme.com/>)

Halozyme Contact

Kurt Gustafson
Chief Financial Officer
(858) 704-8272

kgustafson@halozyme.com (<mailto:kgustafson@halozyme.com>)

SOURCE Halozyme Therapeutics, Inc.

Pharma

Questex

©2025 Questex LLC All rights reserved.

